Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Convertible Debt came in at $235439.0 in Q3 2025, up 55.68% on a QoQ basis from $151237.0 in Q2 2025.

Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Convertible Debt data on file, last reported at $235439.0 in Q3 2025.

Quarterly Convertible Debt changed N/A year-over-year to $235439.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $235439.0 (changed N/A YoY) and the FY2024 annual result came in at $346844.0, changed N/A from the prior year.
Convertible Debt advanced to $235439.0 in Q3 2025, from $151237.0 in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $346844.0 in Q4 2024 to a low of $151237.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-
10	Apimeds Pharmaceuticals US	7.35 Mn	7.35 Mn	-

Download Data